Orchid Pharma Ltd. - Research Center
524372 ORCHIDPHAR Group (T) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 40.82 | 40.82 | 40.82 | 88.96 | 88.96 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 637.14 | 640.52 | 1,015.38 | -843.95 | -763.10 |
| Loan funds | |||||
| Secured loans | 267.95 | 430.34 | 501.47 | 2,120.10 | 2,588.20 |
| Unsecured loans | - | - | - | - | - |
| Total | 945.91 | 1,111.68 | 1,557.67 | 1,365.11 | 1,914.07 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 1,165.92 | 1,165.67 | 1,419.94 | 1,419.36 | 1,558.11 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 582.27 | 495.28 | 381.13 | 258.01 | 266.83 |
| Net block | 583.65 | 670.39 | 1,038.81 | 1,161.35 | 1,291.28 |
| Capital work-in-progress | 9.78 | 7.43 | 88.52 | 278.16 | 271.53 |
| Investments | 49.01 | 15.43 | 0.34 | 0.47 | 124.77 |
| Net current assets | |||||
| Current assets, loans & advances | 451.74 | 531.23 | 584.07 | 1,553.28 | 1,523.19 |
| Less : current liabilities & provisions | 148.28 | 112.79 | 154.07 | 1,628.15 | 1,296.70 |
| Total net current assets | 303.46 | 418.43 | 430.00 | -74.87 | 226.49 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 945.91 | 1,111.68 | 1,557.67 | 1,365.11 | 1,914.07 |
| Notes: | |||||
| Book value of unquoted investments | 173.69 | 125.04 | 125.04 | 125.04 | 125.04 |
| Market value of quoted investments | 0.09 | 0.13 | 0.06 | 0.19 | 0.19 |
| Contingent liabilities | 24.87 | 45.31 | 0.97 | 143.87 | 178.39 |
| Number of equity sharesoutstanding (Lacs) | 408.16 | 408.16 | 408.16 | 889.64 | 889.64 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis